Abstract
Objective
To investigate the relationship between Hormone Therapy (HT) and incidence on anxiety and depression in prostate cancer patients (PCa).
Methods
526 PCa patients completed a survey about their cancer status, treatments received, anxiety and depression status. Total scores on anxiety and depression inventories, plus symptom profiles that discriminated between patients with current HT, past HT, and never having received HT, were compiled for analysis.
Results
Patients who were currently receiving HT had significantly higher total anxiety and depression scores than patients who had previously received HT or who had never received HT. Analysis of the symptoms of anxiety and depression which distinguished between these groups of patients suggested that patients who had never received HT had significantly lower scores than current or past HT patients. Although several symptoms could be directly allocated to PCa and/or HT, symptom profiles were indicative of clinically significant anxiety and/or depression in patients who were currently receiving, or who had previously received, HT
Conclusion
Current HT may lead to symptoms of anxiety and/or depression which require clinical attention. These effects appear to decrease after completion of HT.
To investigate the relationship between Hormone Therapy (HT) and incidence on anxiety and depression in prostate cancer patients (PCa).
Methods
526 PCa patients completed a survey about their cancer status, treatments received, anxiety and depression status. Total scores on anxiety and depression inventories, plus symptom profiles that discriminated between patients with current HT, past HT, and never having received HT, were compiled for analysis.
Results
Patients who were currently receiving HT had significantly higher total anxiety and depression scores than patients who had previously received HT or who had never received HT. Analysis of the symptoms of anxiety and depression which distinguished between these groups of patients suggested that patients who had never received HT had significantly lower scores than current or past HT patients. Although several symptoms could be directly allocated to PCa and/or HT, symptom profiles were indicative of clinically significant anxiety and/or depression in patients who were currently receiving, or who had previously received, HT
Conclusion
Current HT may lead to symptoms of anxiety and/or depression which require clinical attention. These effects appear to decrease after completion of HT.
| Original language | English |
|---|---|
| Pages (from-to) | 56-57 |
| Number of pages | 2 |
| Journal | BJU International |
| Volume | 112 |
| DOIs | |
| Publication status | Published - Aug 2013 |
